Slide 1: Elevating the World’s Wellbeing
Elevating the World’s Wellbeing Q2 2026 Financial Results and Business Update
Slide 2: Forward-looking statement
Q22026 TRADING UPDATE Forward-looking statement This presentation contains certain forward-looking statements and or implicitly assumed or described in those statements or to turn opinions. Forward-looking statements are statements that do not out to be less favourable than the results expressly or
Slide 3: Agenda
Q22026 TRADING UPDATE Agenda Q2 2026: Snapshot Business Updates Financial Results Share buyback Strategy and Outlook Q&A Henrik Molin Matthew Poulter CEO & Founder CFO
Slide 4: Q2 2026 Snapshot / Verdict
Q22026 TRADING UPDATE Q2 2026 Snapshot / Verdict WHAT IMPROVED WHAT SLOWED EXIT POSITION Quarterly revenue up 10% from Annualised revenue run-rate Adj. EBITDA margin 34% (-4pp YoY), Q42026; 8% YoY to €3.1m and 96% €13.6m (+7% QoQ / +3% YoY) planned investment in sales & of revenue from subscriptions
Slide 5: Q2 Financial Highlights
Q22026 TRADING UPDATE Q2 Financial Highlights REVENUE ADJUSTED EBITDA Group ARR FCF (continuting operations exc legal settlement) €3.4m €1.2m €13.6m €0.1m YOY QOQ YOY QOQ YOY QOQ Q2 2025 8% 6% -3% +7% 3% 7% €0.1m CONSTANT CURRENCY 7% RECURRING REVENUE SaaS GROSS MARGIN CONSECUTIVE QUARTERS POSITIVE
Slide 6: Lifecare Q226 update
Q22026 TRADING UPDATE Lifecare Q226 update YOY REVENUE GROWTH CHURN 11% Q22026 REVEUNE 1% €3.1m In-line with prior quarter and year Lifecare - Licence Base Back in Growth, Pricing Power Holding Q22026 ADJUSTED EBITDA / Q22026 ADJUSTED EBITDA LESS MARGIN CAPEX / MARGIN ARR of €12.7m, +7% YoY, +8% QoQ
Slide 7: Wellness Q22026 update
Q22026 TRADING UPDATE Wellness Q22026 update YOY REVENUE GROWTH Q22026 ADJUSTED EBITDA / MARGIN Q22026 ADJUSTED EBITDA LESS CAPEX / MARGIN -14% CURRENT ANNUAL RECURRING REVENUE €0.1m / 32% €36k / 11% €0.9m (Q22025 : €2k / 1%) (Q22025 : (€0.1m) / -14%) Wellness - Profitability Sustained Into a Second
Slide 8: 2026 Execution priorities
Q22026 TRADING UPDATE 2026 Execution priorities Q2 Progress update North America Acceleration Product Unification & Value Expansion NYC commercial hub fully operational RTM live in production since the June 2026 launch RTM commercially launched in June 2026; first paying US Unified HEP + RTM + PT Co
Slide 9: Financial Results
Q22026 TRADING UPDATE Financial Results
Slide 10: Q22026 Financial Summary
Q22026 TRADING UPDATE Q22026 Financial Summary Metric €m Q22026 Q22025 -3% Revenue 3.4 3.2 8% Revenue in line with forecast, 6% ahead of Q1 Adjusted EBITDA 6% ahead of forecast; H1 Constant currency running 7% ahead of budget 3.4 3.2 7% revenue Margin move is planned investment (North America, RTM),
Slide 11: Consistent quarterly revenue growth
Q22026 TRADING UPDATE Consistent quarterly revenue growth Revenue has compounded every quarter since 2021, €1.4m to €3.4m Q2 2026 a new quarterly high, ahead of Q1 2026 +8% YoY (7% cc); +10% vs Q4 2025 over six months Lifecare drives the growth; Wellness now smaller but profitable post- restructurin
Slide 12: Profitability
Q22026 TRADING UPDATE Profitability 34% Adjusted EBITDA margin, sustained for a sixth straight quarter above 34%
Slide 13: Financial Position at Q22026 Close
Q12026 Trading Q22026 TRADINGUpdate UPDATE Financial Position at Q22026 Close Free cash flow Liquidity vs. Q126 Cash conversion vs. Q225 Capital Flexibility vs. Q126 Cash €0.4m (€0.4m) Operating cash flow €0.7m (€0.9m) Adjusted EBITDA margin: 34% (34%) RCF drawn €4.3m (€4.0m) FCF (€0.2m) (€0.1m) Net
Slide 14: Share Buyback
Q22026 TRADING UPDATE Share Buyback Funding the new management incentive plan - without issuing a single new share 2026 PROGRAMME SHAREHOLDER AUTHORITY FIRST PURCHASE €120k 10% August Up to €250k p.a. from 2027 1,626,077 shares • AGM 26 May 2026 Following required statutory fillings WHAT IT IS PURPO
Slide 15: Strategy and Outlook
Q12026 Trading Q22026 TRADINGUpdate UPDATE Strategy and Outlook
Slide 16: Why Physitrack Is Positioned to Win
Q22026 TRADING UPDATE Why Physitrack Is Positioned to Win Clinically Embedded SaaS Platform Recurring, High-Margin Revenue Model Deep integration into practitioner workflows 96% subscription revenue High switching costs through embedded exercise, 90% SaaS gross margin in Lifecare outcomes and telehe
Slide 17: How it all comes together - Investing in Physitrack
Q22026 TRADING UPDATE How it all comes together - Investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Physitrack aims to achieve a doubling of revenue Growing market supported by 1. Market growth dynamics within the medium term, replacing the
Slide 18: Q&A
Q&A